In the General/Chat forum, on a thread titled Common diabetes drug linked to lower rate of long COVID, mewzilla wrote: From a paper published last month, get a load of this... Looks like the NIH is circling the wagons. The NIH contributed to the research in 4 different capacities.
At your link - here's the disclosure for potential conflict of interest (mostly pharmas)
Potential conflicts of interest. J. B. B. reports contracted fees and travel support for contracted activities for consulting work paid to the University of North Carolina by Novo Nordisk; grant support by NIH, PCORI, Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; personal compensation for consultation from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, and Vertex.; personal compensation for expert testimony from Medtronic MiniMed; participation on advisory boards for Altimmune, AstraZeneca, and Insulet; a leadership role for the Association of Clinical and Translational Science; and stock/options in Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. M. A. P. receives consulting fees from Opticyte and Cytovale. A. B. K. has served as an external consultant for Roche Diagnostics; received speaker honoraria from Siemens Healthcare Diagnostics, the American Kidney Fund, the National Kidney Foundation, the American Society of Nephrology, and Yale University Department of Laboratory Medicine; research support unrelated to this work from Siemens Healthcare Diagnostics, Kyowa Kirin Pharmaceutical Development, the Juvenile Diabetes Research Foundation, and the NIH; support for travel from College of American Pathologists Point-Of-Care Testing Committee; participation on an advisory board for the Minnesota Newborn Screening Advisory Committee; grants from NIH and JDRF for multiple unrelated clinical research projects and Kyowa Kirin Pharmaceutical Development and Siemens Healthcare Diagnostics for unrelated clinical research studies; and leadership roles for the American Board of Clinical Chemistry, Association for Diagnostics and Laboratory Medicine (ADLM) Evidence-Based Laboratory Medicine Subcommittee, and ADLM Academy Test Utilization Committee. M. R. R. reports consulting fees from 20/20 Gene Systems for coronavirus disease 2019 testing. D. B. R. reports grants from the NIH NCATS ACTIV-6 Steering Committee Chair. K. C. reports stock or stock options for United Health Group. C. T. B. reports consulting fees from NCATS/DCRI and the ACTIV-6 Executive Committee and support for travel from Academic Medical Education. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclo
I didn't know the FDA has no authority to issue a mandatory recall due to manufacturing problems, and that they don't seem to want that authority. Makes sense - they wouldn't want to recall the Covid 'vax'.
In 2020 there was a recall of certain Metaformin products.
I thought this quote was interesting:
"A few months ago, Singapore, Canada and Switzerland recalled several metformin products from pharmacy shelves because regulators became aware of contamination with the probable carcinogen NDMA. Now, the FDA is notifying health professionals that metformin from five manufacturers may also be tainted. Those companies include Actavis, Amneal, Apotex, Lupin and Marksans.
At the time of this writing only Amneal and Apotex have announced recalls of their extended-release metformin formulations. Most health professionals and patients do not realize that in the United States the FDA has no authority to issue a mandatory recall due to manufacturing problems. As far as we can tell, the agency does not want this authority, which we find astonishing."